119th Congress · introduced in the House · Feb 24, 2025
Protecting Life from Chemical Abortions Act
Official title from Congress.gov
Latest action (Feb 24, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 24, 2025)
Protecting Life from Chemical Abortions Act
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers.
The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention.
The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Abortion · Drug safety, medical device, and laboratory regulation · Drug therapy · Government information and archives · Health information and medical records · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
3 citations.
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$420,000
Spent on own lobbying
…pristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accoun…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Family issues/Abortion/Adoption
$420,000
Spent on own lobbying
…pristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accoun…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Pharmacy
$420,000
Spent on own lobbying
…pristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate & Complete Abortion Data Reporting Act; H.R. 6466 Forced Abortion Prevention and Accoun…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing